A5082156303- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Radiation Dose and Imaging
- Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- DNA Repair Mechanisms
- Radiation Therapy and Dosimetry
- Cancer therapeutics and mechanisms
- Surgical site infection prevention
- Economic and Financial Impacts of Cancer
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Colorectal and Anal Carcinomas
- Neutropenia and Cancer Infections
- Axon Guidance and Neuronal Signaling
- Diagnosis and treatment of tuberculosis
University College London
2023-2024
University of Campania "Luigi Vanvitelli"
2018-2023
Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment cetuximab plus avelumab overall survival (OS) may be worthy investigation this setting.To assess the efficacy and safety rechallenge avelumab.This single-arm, multicenter phase 2 trial enrolled from August 2018 February...
Tumor heterogeneity represents a possible cause of error in detecting predictive genetic alterations on tumor tissue and can be overcome by testing circulating DNA (ctDNA) using liquid biopsy. We assessed 72 consecutive patients with diagnosis metastatic colorectal cancer (mCRC) Idylla™ Biocartis, fully automated platform that evaluates the most frequent mutations KRAS, NRAS BRAF genes. correlated results biopsy standard tissue-based next generation sequencing (NGS) analyses to patient...
TPS731 Background: The immune system plays a crucial role in modulating response to monoclonal antibodies therapy cancer. Novel immunecheckpoint inhibitors have demonstrated potent efficacy alone and combinations with cytotoxic agents several cancers. In this regard, avelumab combination cetuximab might be relevant rechallenge strategy RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients treated first-line chemotherapy (CT) anti-EGFR drugs who achieved complete or partial...
3578 Background: Promising antitumor activity of so called rechallenge treatment with anti-epidermal growth factor receptor (EGFR) drugs in patients RAS wild type (RAS WT) metastatic colorectal cancer (mCRC) has been recently reported. Beside the absence resistance mutations at plasma circulating tumor DNA (ctDNA) analysis, no biomarkers response to anti-EGFR strategy have identified. Methods: We conducted single arm phase II CAVE mCRC trial evaluate combination cetuximab as plus avelumab 77...
Abstract Objective. Computational anatomical models have many applications in paediatric radiotherapy. Age-specific computational were historically developed to represent average and/or healthy individuals, where cancer patients may present with variations caused by the disease treatment effects. We RT-PAL, a library of age-specific voxelized tailored radiotherapy population. Approach. Data from undergoing craniospinal irradiation (CSI) used (n = 74, median age 7.3y, range: 1–17y). The...
Abstract According to the consensus molecular subtypes (CMS), almost 23% of human colorectal cancer (CRC) are classified in CMS4 group, characterized by a mesenchymal signature and activation transforming growth factor β (TGF-β) signaling. AXL is tyrosine kinase receptor involved epithelial transition, angiogenesis immune modulation CRC. We have previously demonstrated that gene amplified approximately 5% CRC, inhibition causes significant blockade CRC cell proliferation migration. Here we...
According to the consensus molecular subtypes (CMS), almost 23% of human colorectal cancer (CRC) are classified in CMS4 group, characterized by a mesenchymal signature and activation transforming growth factor β (TGF-β) signaling. AXL is tyrosine kinase receptor involved epithelial transition, angiogenesis immune modulation CRC. We have previously demonstrated that gene amplified approximately 5% CRC, inhibition causes significant blockade CRC cell proliferation migration. Here we evaluated...
Abstract DNA damage response (DDR) is crucial in a variety of tumors and several new drugs that interfere with this mechanism are already available or advanced clinical testing. RAS-MAPK pathway activation, induced by either RAS BRAF mutation, frequent feature colorectal cancers (CRCs) strongly associated to mitotic stress dependency upon DDR. Among the used for CRC, oxaliplatin irinotecan known induce form single double strand breaks (SSB/DSBs) thus require active DDR systems cancer cells...